Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S is an electrolyte and fluid replenisher. It provides water and essential electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) to restore and maintain extracellular fluid volume and electrolyte balance. Acetate and gluconate are metabolized to bicarbonate, serving as bicarbonate precursors to help correct metabolic acidosis.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
FDA: Replacement of extracellular fluid and electrolytes in patients with fluid and electrolyte deficits, maintenance of fluid and electrolyte balance during surgery or in postoperative patients.,Off-label: Treatment of metabolic acidosis, correction of electrolyte imbalances.
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous administration, typical adult dose is 500-1000 m L per hour, adjusted based on clinical status and electrolyte needs.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
The terminal elimination half-life for the individual electrolytes varies: Sodium has a half-life of approximately 2-4 hours depending on hydration and renal function; potassium has a half-life of 5-7 hours in normal renal function; magnesium has a half-life of 24-72 hours; calcium has a half-life of 3-6 hours. Clinically, the half-life is prolonged in renal impairment, necessitating dose adjustment.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Acetate and gluconate are metabolized via the tricarboxylic acid (TCA) cycle primarily in the liver, producing bicarbonate; acetate is also metabolized peripherally. Sodium, potassium, magnesium, and chloride are excreted renally with minimal hepatic metabolism.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
The electrolytes in ISOLYTE S are primarily excreted via renal elimination. Sodium and chloride are almost entirely excreted by the kidneys, with minimal biliary or fecal elimination (<2%). Potassium is predominantly excreted renally (90%), with approximately 10% eliminated via feces. Magnesium and calcium are mainly excreted in urine (70-80% for magnesium, 20-30% for calcium) with some biliary/fecal excretion. Acetate and gluconate are metabolized to bicarbonate and excreted renally.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Minimal protein binding for most electrolytes: sodium (<5%), potassium (<5%), chloride (<5%), and magnesium (20-30% to albumin). Calcium is 40-50% bound to albumin and other proteins. Acetate and gluconate are not protein bound.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Sodium: Vd of 0.25-0.35 L/kg, reflecting distribution primarily in extracellular fluid. Potassium: Vd of 0.4-0.6 L/kg, distributed in both intracellular and extracellular fluid. Magnesium: Vd of 0.5-0.8 L/kg. Calcium: Vd of 0.2-0.3 L/kg. These values indicate that electrolytes distribute widely but predominantly in various body compartments.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Bioavailability is 100% for all components when administered intravenously. For oral administration (not applicable here), bioavailability would vary, but for IV formulation, complete bioavailability is assumed.
Intravenous: 100% bioavailability.
For GFR <30 m L/min, use with caution and monitor electrolytes; dose reduction may be required based on serum potassium and other electrolytes.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalance.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Pediatric dosing is weight-based: 20-30 m L/kg as a single dose, then titrate based on clinical response and electrolyte levels.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Geriatric patients: use lower initial doses (e.g., 250-500 m L over 2-4 hours) and monitor for fluid overload and electrolyte disturbances due to decreased renal function.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
None.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Risk of fluid overload and congestive heart failure in patients with renal impairment or cardiac disease.,Electrolyte disturbances: hypernatremia, hyperkalemia, hypermagnesemia, hyperchloremia, acidosis or alkalosis.,Use with caution in patients with severe renal impairment, liver disease, or conditions predisposing to electrolyte imbalances.,Avoid rapid infusion in patients with increased intracranial pressure.
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Hyperkalemia (elevated potassium levels).,Hypernatremia (elevated sodium levels).,Hypermagnesemia (elevated magnesium levels).,Acute renal failure with oliguria or anuria.,Hypersensitivity to any component.
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No specific food interactions. Monitor sodium and fluid intake in patients with hypertension, heart failure, or renal impairment.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
FDA pregnancy category C. No well-controlled studies in pregnant women. Use only if clearly needed. No specific fetal risks known; risk-benefit assessment required.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Compatible with breastfeeding. ISOLYTE S is an electrolyte solution with no known excretion into breast milk; components are normal plasma constituents. M/P ratio not applicable.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No specific dose adjustments required during pregnancy. Dosing based on clinical assessment of fluid and electrolyte deficits; physiological changes in pregnancy may necessitate adjustments in infusion rate and volume.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
ISOLYTE S is a balanced electrolyte solution for maintenance and replacement therapy. Contains acetate and gluconate as bicarbonate precursors; avoid in patients with severe metabolic alkalosis or hyperkalemia. Use with caution in renal impairment, heart failure, or edema. Monitor serum electrolytes, acid-base balance, and renal function. Do not administer simultaneously with blood products via same IV line due to risk of hemolysis.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This solution is used to replace fluids and electrolytes in your body.,Tell your doctor if you have kidney disease, heart failure, or fluid retention.,Report any swelling, shortness of breath, or irregular heartbeat.,Do not drink alcohol while receiving this treatment.,Follow any dietary restrictions as advised by your healthcare provider.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S is an electrolyte and fluid replenisher. It provides water and essential electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) to restore and maintain extracellular fluid volume and electrolyte balance. Acetate and gluconate are metabolized to bicarbonate, serving as bicarbonate precursors to help correct metabolic acidosis.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S IN PLASTIC CONTAINER is: Intravenous administration, typical adult dose is 500-1000 m L per hour, adjusted based on clinical status and electrolyte needs.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S IN PLASTIC CONTAINER is classified as Category C. FDA pregnancy category C. No well-controlled studies in pregnant women. Use only if clearly needed. No specific fetal risks known; risk-benefit assessment required.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.